Injectable antiretroviral drug Lenacapavir (LEN) is approved for the prevention of HIV: Let’s move with speed, scale and equity
The approval of injectable Lenacapavir (LEN) for HIV prevention is one of the most important developments in the three-decade response to the HIV pandemic. Developed by Gilead Sciences, LEN is a twice-yearly injectable option for HIV pre-exposure prophylaxis (PrEP) that showed nearly...